OQS
ELVN icon

Occudo Quantitative Strategies’s Enliven Therapeutics ELVN Stock Holding History

Occudo Quantitative Strategies’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,563
Closed -$41K – 1175
2021
Q4 		$41K Sell
4,563
-43
-0.9% -$564 ﹤0.01% 1018
2021
Q3 		$75K Buy
4,606
+1,982
+76% +$41.2K 0.01% 940
2021
Q2 		$83K Buy
+2,624
New +$81.4K 0.01% 810

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Occudo Quantitative Strategies's ELVN Position: Q1 2022 in Review

Occudo Quantitative Strategies sold out of Enliven Therapeutics (ELVN) in Q1 2022, closing a stake of 4,563 shares — an estimated $41K sold.

Occudo Quantitative Strategies first reported a position in ELVN in Q2 2021 and held it in 3 quarters. The position peaked at $83K in Q2 2021. 31 funds tracked by Wall St. Rank hold ELVN as of Q1 2022.

  • Occudo Quantitative Strategies reported no remaining Enliven Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 4,563 Enliven Therapeutics shares in Q1 2022, an estimated $41K.
  • Occudo Quantitative Strategies first reported a position in Enliven Therapeutics in Q2 2021 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Enliven Therapeutics position peaked at $83K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2022, filed 16 May 2022.